Kamada (KMDA) Income from Continuing Operations (2012 - 2026)
Kamada's (KMDA) quarterly Income from Continuing Operations came in at 6650000.0 in Q1 2026, down 28.2% YoY from 9262000.0 in Q1 2025, and up 12.6% on a QoQ basis from 5906000.0 in Q4 2025.
Kamada (KMDA) Income from Continuing Operations (2012 - 2026) Analysis & Trends
Kamada (KMDA) has 15 years of Income from Continuing Operations data on file, last reported at 6650000.0 in Q1 2026.
- Quarterly Income from Continuing Operations fell 28.2% year-over-year to 6650000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 20000328.0 (up 38.82% YoY) and the FY2025 annual result came in at 26736000.0, up 119.04% from the prior year.
- Income from Continuing Operations grew to 6650000.0 in Q1 2026, from 5906000.0 in the prior quarter.
- In the past five years, Income from Continuing Operations ranged from a high of 9262000.0 in Q1 2025 to a low of 1809.0 in Q1 2023.
- A 5-year average of 3292157.12 and a median of 3223000.0 in 2023 frame the typical range for Income from Continuing Operations.
- The widest YoY moves for Income from Continuing Operations: up 537066.67% in 2023, down 100.1% in 2023.
- Tracing KMDA's Income from Continuing Operations over 5 years: stood at 3247000.0 in 2022, then surged by 53.68% to 4990000.0 in 2023, then sank by 77.76% to 1110000.0 in 2024, then surged by 432.07% to 5906000.0 in 2025, then advanced by 12.6% to 6650000.0 in 2026.
- The last three Income from Continuing Operations figures came in at 6650000.0 (Q1 2026), 5906000.0 (Q4 2025), and 7438000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.98 Bn | 43.02 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.28 Bn | 39.62 Bn | 2.15 Bn | -576.00 Mn |
| 3 | Zoetis | 31.78 Bn | 30.11 Bn | 1.05 Bn | 866.00 Mn |
| 4 | Takeda Pharmaceutical | 28.71 Bn | 22.91 Bn | 5.10 Bn | 1.33 Bn |
| 5 | United Therapeutics | 22.25 Bn | 19.59 Bn | 683.80 Mn | 333.00 Mn |
| 6 | Viatris | 18.72 Bn | 17.83 Bn | 1.46 Bn | -118.80 Mn |
| 7 | Neurocrine Biosciences | 15.57 Bn | 15.18 Bn | 935.80 Mn | 144.40 Mn |
| 8 | Elanco Animal Health | 11.87 Bn | 11.34 Bn | 798.00 Mn | 54.00 Mn |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.97 Bn | - | - |
| 10 | Kamada | 464.05 Mn | 434.58 Mn | 22.47 Mn | 9.26 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 9.26 Mn |
| Mar 31, 2026 | 6.65 Mn |
| Dec 31, 2025 | 5.91 Mn |
| Sep 30, 2025 | 7.44 Mn |
| Jun 30, 2025 | 6,328.00 |
| Mar 31, 2025 | 9.26 Mn |
| Dec 31, 2024 | 1.11 Mn |
| Sep 30, 2024 | 4.03 Mn |
| Jun 30, 2024 | 4,552.00 |
| Mar 31, 2024 | 2.51 Mn |
| Dec 31, 2023 | 4.99 Mn |
| Sep 30, 2023 | 3.22 Mn |
| Jun 30, 2023 | 1.81 Mn |
| Mar 31, 2023 | -1,809.00 |
| Dec 31, 2022 | 3.25 Mn |
| Sep 30, 2022 | 600.00 |
| Jun 30, 2022 | 3.95 Mn |
| Mar 31, 2022 | 1.83 Mn |
| Dec 31, 2021 | -4.82 Mn |
| Sep 30, 2021 | 868,000.00 |